BC Cancer - Vancouver, Vancouver, BC, Canada
Tharani Krishnan , Joao Paulo Solar Vasconcelos , Emma Titmuss , James Thomas Topham , David F. Schaeffer , Aly Karsan , Howard J Lim , Cheryl Ho , Sharlene Gill , Hagen Fritz Kennecke , Eric Xueyu Chen , Daniel John Renouf , Christopher J. O'Callaghan , Jonathan M. Loree , Derek J. Jonker
Background: Clonal hematopoesis of indeterminate potential (CHIP) is the acquisition of somatic mutations leading to clonal expansion of hematopoietic stem cells and is a common incidental finding in circulating tumor DNA (ctDNA). Inflammation from these cells or a reduced marrow reserve may impact treatment outcomes or adverse events. We investigated the incidence of CHIP in ctDNA from patients with gastrointestinal (GI) cancers and explored its association with outcomes and adverse events (AEs). Methods: We collected ctDNA results from a local prospective metastatic colorectal cancer (mCRC) cohort (PREDICT-L) and ctDNA data from two randomized trials: CCTG CO.26 (durvalumab + tremelimumab [D+T] or best supportive care [BSC] in mCRC) and CCTG PA.7 (gemcitabine and nab-paclitaxel [GN] with or without D+T in metastatic pancreatic adenocarcinoma [mPDAC]). CHIP+ was defined as the presence of a variant of ≥2% variant allele frequency annotated in the ctDNA report in any of the genes DNMT3A, TET2, ASXL1 and ATM, and not annotated as germline by respective sequencing platforms. The first line of treatment after ctDNA was reviewed, and grade ≥3 or dose-limiting adverse events were documented. Results: The prevalence of CHIP varied from 10% to 18% (see table). CHIP+ patients were older than CHIP- in the CO.26 cohort (p=0.011), and ECOG was higher in CHIP+ patients in the PREDICT-L cohort. There was no difference between CHIP+/- patients with regards to sex. DNMT3A was the gene most frequently mutated in all three cohorts. There was no significant difference in PFS or OS between the CHIP+/- groups, both in those treated with chemotherapy (Chemo) or immunotherapy (IO). The most common AEs were rash, GI toxicities and bleeding/clotting abnormalities. There was no significant difference in the rates of AEs between the CHIP+/- groups for those treated with Chemo or IO. Conclusions: CHIP is a common alteration in ctDNA but did not impact PFS, OS, or the chance of developing an AE.
CO.26 D+T vs BSC (n= 169) | PA.7 D+T + GN vs GN (n=173) | PREDICT-L Physician choice (n=41) | |
---|---|---|---|
Tumor type | mCRC | mPDAC | mCRC |
Assay Used | GuardantOMNI | Predicine Atlas | FoundationOne Liquid CDx |
Median Age years (interquartile range) | 65 (58-72) | 65 (58-70) | 66 (61-72) |
CHIP Prevalence n (%) | 30 (18) | 18 (10) | 7 (17) |
Hazard Ratio (HR) or Odds Ratio (OR) CHIP+ versus CHIP- [95% confidence interval] P-value | |||
---|---|---|---|
PFS HR Chemo IO +/- Chemo | 1.53 [0.76-3.10] p=0.23 0.98 [0.57-1.66] p=0.93 | 0.60 [0.31-1.13] p=0.11 1.65 [0.57-4.75] p=0.35 | 0.66 [0.13-3.28] p=0.62 N/A |
OS HR Chemo IO +/- Chemo | 1.15 [0.59-2.27] p=0.68 1.26 [0.73-2.16] p=0.41 | 0.55 [0.17-1.78] p=0.32 0.76 [0.39-1.46] p=0.403 | N/A N/A |
AEs OR Chemo IO +/- Chemo | N/A 0.92 [0.091-4.76] p=1 | 1.44 [0.098-21.3] p=1 1.19 [0.33-4.31] p=0.78 | 1.49 [0.20-17.92] p=1 N/A |
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2023 ASCO Annual Meeting
First Author: Kanchi Patell
2023 ASCO Annual Meeting
First Author: Anne Hansen Ree
2023 ASCO Annual Meeting
First Author: Federica Grosso
2024 ASCO Breakthrough
First Author: Teerada Siripoon